Recently, another mapping-focused study has been performed using samples from patients with or without anti-citrullinated peptide antibodies (ACPA, a type of autoantibody observed in roughly two-thirds of patients with established RA) in a cohort with minimal treatment intervention (19). The gene discussed is PRTN3; the disease is rheumatoid arthritis.